genedrive plc FY25 Results: Revenue Doubles Amid Going Concern Warning

Commercial ramp: where the growth is coming from

Total income rose to £1.0m, with £0.65m generated in H2. Management says it has current visibility for around £0.9m of total income already in FY26, driven by:

• Completion and submission of NICE EVA real‑world evidence for MT‑RNR1.
• Scotland’s phased national implementation of MT‑RNR1 and a CYP2C19 point‑of‑care pilot versus lab pathways, both started in October 2025.
• Manchester Foundation Trust’s 12‑month Acute Coronary Syndrome expansion using rapid CYP2C19 genotyping.

Internationally, early sales and distributor set‑ups are under way in Europe and the Middle East, including Italy, the Netherlands, UAE, Bahrain, Kuwait, Saudi Arabia and Qatar.

Cash, funding and going concern: the crux of the investment case

The board is frank: with £0.32m cash at 30 November 2025 and average burn of c.£0.35m per month, additional finance is needed “in the very near term”. The post year‑end conditional £3.6m equity raise did not complete after shareholders withheld approval; only £0.8m from the firm placing was received. Heads of terms are agreed for a £1.0m loan from the largest shareholder and discussions are progressing. Directors have taken a 20% pay cut until funding materially extends the runway through 2026.

The auditors included a going concern material uncertainty paragraph. That does not mean failure is inevitable; it means the funding outcome is not within management’s complete control. In my view, this is the key near‑term swing factor for the share price and for delivery of the US regulatory plan.

Why the operational progress matters for the NHS and beyond

• CYP2C19 at the point of care can move stroke patients to the right antiplatelet within about 70 minutes. The NHS Implementation Guide and NICE backing are strong catalysts for scale.
• MT‑RNR1 delivers a 26‑minute result in neonatal units, preventing severe, lifelong hearing loss. Real‑world UK data and Scotland’s national roll‑out are powerful reference points for export markets.
• Both products sit on the NHS DPS, lowering procurement friction, and both have CE‑IVD/NICE credentials – important badges for EU and Middle East markets.

Risks and watch‑outs

• Financing risk: completion of the £1.0m loan is not yet binding. Further capital will likely be required to bridge to profitability and to fund US submissions.
• Revenue timing: NHS adoption cycles and evidence generation can be slow; the £0.9m FY26 visibility is not the same as secured orders.
• R&D tax credit: the £0.4m receivable is “not assured” and depends on working capital to complete the claim process.
• Regulatory timelines: CYP2C19 510(k) now targeted for late‑Q4 FY26 and MT‑RNR1 de novo towards end‑2026 – both contingent on runway.

My take: solid clinical and policy positioning, but funding dictates the outcome

There is a lot to like operationally. genedrive has two CE‑IVD, NICE‑recommended, near‑patient genetic tests in routine NHS use, visible national roll‑out in Scotland, encouraging international pilots, and US routes defined with the FDA. Revenue doubled to £1.0m, and the loss narrowed to £5.2m despite the shift to commercial activities.

The counterweight is the balance sheet. With £0.32m at the end of November and burn of roughly £0.35m a month, execution now hinges on closing the £1.0m loan and mapping a longer‑term funding plan. If financing lands, the combination of NICE support, NHS procurement access and real‑world outcomes offers a credible runway to scale. If not, investors should be prepared for further dilution or strategic alternatives.

Bottom line: the clinical case is compelling; the commercial case is building; the funding case remains critical. This is high potential, high risk – and very news‑driven in the near term.